BRPI0508534A - moduladores de canais iÈnicos - Google Patents

moduladores de canais iÈnicos

Info

Publication number
BRPI0508534A
BRPI0508534A BRPI0508534-9A BRPI0508534A BRPI0508534A BR PI0508534 A BRPI0508534 A BR PI0508534A BR PI0508534 A BRPI0508534 A BR PI0508534A BR PI0508534 A BRPI0508534 A BR PI0508534A
Authority
BR
Brazil
Prior art keywords
ion channel
compounds
channel modulators
compositions
disease
Prior art date
Application number
BRPI0508534-9A
Other languages
English (en)
Inventor
Robert Zelle
Vincent P Galullo
Paul Will
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0508534A publication Critical patent/BRPI0508534A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

MODULADORES DE CANAIS IÈNICOS. A presente invenção refere-se a compostos, composições compreendendo os compostos, e métodos para usar os compostos e composições de compostos. Os compostos, composições, e métodos descritos neste relatório podem ser usados para a modulação terepêutica da função de canais iónicos, e tratamento de doença e sintomas de doenças, particularmente as mediadas por alguns alvos de subtipos de canais de cálcio.
BRPI0508534-9A 2004-03-08 2005-03-07 moduladores de canais iÈnicos BRPI0508534A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55158004P 2004-03-08 2004-03-08
PCT/US2005/007911 WO2005087228A1 (en) 2004-03-08 2005-03-07 Ion channel modulators

Publications (1)

Publication Number Publication Date
BRPI0508534A true BRPI0508534A (pt) 2007-08-14

Family

ID=34975315

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508534-9A BRPI0508534A (pt) 2004-03-08 2005-03-07 moduladores de canais iÈnicos

Country Status (8)

Country Link
US (1) US20070208064A1 (pt)
EP (1) EP1722785A4 (pt)
JP (1) JP2007527915A (pt)
CN (1) CN1938021A (pt)
AU (1) AU2005221683A1 (pt)
BR (1) BRPI0508534A (pt)
CA (1) CA2557665A1 (pt)
WO (1) WO2005087228A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005086836A2 (en) * 2004-03-08 2005-09-22 Wyeth Ion channel modulators
AU2005222402A1 (en) * 2004-03-08 2005-09-22 Wyeth Ion channel modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2032289A1 (en) * 1989-12-29 1991-06-30 Joseph A. Finkelstein Substituted 5-(alkyl) carboxamide imidazoles
NZ239161A (en) * 1990-07-31 1994-01-26 Smithkline Beecham Corp Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments,
DE69131021T2 (de) * 1990-12-14 1999-08-12 Smithkline Beecham Corp Angiotensin-ii-rezeptor blockierende zusammensetzungen
DE60003025T2 (de) * 1999-04-02 2004-03-18 Bristol-Myers Squibb Pharma Co. Arylsulfonyle als faktor xa inhibitoren
WO2005086836A2 (en) * 2004-03-08 2005-09-22 Wyeth Ion channel modulators
WO2005086895A2 (en) * 2004-03-08 2005-09-22 Wyeth Ion channel modulators

Also Published As

Publication number Publication date
CA2557665A1 (en) 2005-09-22
JP2007527915A (ja) 2007-10-04
CN1938021A (zh) 2007-03-28
EP1722785A4 (en) 2009-07-08
AU2005221683A1 (en) 2005-09-22
WO2005087228A1 (en) 2005-09-22
US20070208064A1 (en) 2007-09-06
EP1722785A1 (en) 2006-11-22

Similar Documents

Publication Publication Date Title
BRPI0508594A (pt) moduladores de canal de ìon
BRPI0508532A (pt) moduladores do canal de ìon
BRPI0508556A (pt) moduladores de canal iÈnico
BRPI0508522A (pt) moduladores de canal de ìon
BRPI0508537A (pt) moduladores do canal de ìon
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
TW200730515A (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
EA200700225A1 (ru) Аналоги тетрапептида
EA200801897A1 (ru) Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений
EA200701471A1 (ru) Замещённые пиридинильные и пиримидинильные производные, используемые в качестве модуляторов метаболизма и лечение ассоциированных с ним расстройств
EA200602129A1 (ru) Новое применение пептидных соединений для лечения дискинезии
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
WO2007095050A3 (en) N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA201170349A1 (ru) Модуляторы mif
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
EA200870497A1 (ru) Бензимидазольные модуляторы vr1
BRPI0615097A2 (pt) agentes para previnir e tratar distúrbios que envolvem modulação dos receptores de ryr
EA201001639A1 (ru) Композиции и способы их получения и применения

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE A 8.6 NA RPI 2099 DE 29/03/2011.